SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

BioCorRx (BICX)

BICX RSS Feed
Add BICX Price Alert      Hide Sticky   Hide Intro
Moderator: MU_Redskin1, Pip611
Search This Board: 
Last Post: 12/15/2017 8:16:36 PM - Followers: 128 - Board type: Free - Posts Today: 3

 

 

About BioCorRx

Program Overview

BioCorRx (OTCBB: BICX) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a treatment program that is used by various licensed alcohol addiction clinics throughout the United States.

The program consists of two components:BioCorRx has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol for as long as a year in some patients, depending on individual metabolism rates.BioCorRx also owns a life coaching program that is tailored specifically to alcoholics. Once a patient has received the implant, they are encouraged to enter the life coaching program to maximize results.

BioCorRx’s revolutionary alcohol treatment program has an 85% success rate as reported by patients in routine telephone and face to face interviews. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private life coaching program without co-workers or family members knowing, unless they so choose.

Technology

Naltrexone is a medication that blocks the effects of drugs known as opioids and was approved by the FDA in 1995 for the treatment of alcohol dependence.

Learn more about the side effects of naltrexone.

Naltrexone blocks the parts of the brain that "feel pleasure” when patients use alcohol. When these areas of the brain are blocked, patients feel significantly less cravings for alcohol and even if alcohol is used, the effects of it will be extremely limited - making sobriety the only option. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient's psychological needs. The combination of these treatments has resulted in the highest chance of sobriety.

naltrexone implant

While other companies use naltrexone in their treatments, the drug is typically administered in oral or injection form, requiring their patients to be responsible for taking the medication or scheduling an appointment.

While some patients do well with the oral formulation, there is a drawback that it must be taken daily and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Patients who received the program developed by BioCorRx are treated with a slow release dose that can last up to year in many patients (depending on various factors such as metabolism rates), which gives the patients a higher success rate for the treatment of alcoholism.

The outpatient naltrexone implant procedure can take as little as 20 minutes under local anesthetic in some cases. Most patients can return to work or their daily routine in the same day, without the cravings for alcohol.

Mission, Vision, Values

Mission

BioCorRx is focused on providing leadership and innovation for the treatment of alcoholism by offering a high-quality, comprehensive and cost-effective recovery program that allows patients and their loved ones to celebrate freedom from the cycle of alcohol addiction. Our program is built on a strong foundation of experience and practice, allowing for an improved quality of life for recovering alcoholics.

Vision

BioCorRx strives to be the preeminent, long-term alcohol recovery program used by treatment centers around the world for alcoholics, as well as their family and friends. By providing patients a "Fresh Start" on life, they have the opportunity to live happier, healthier, more productive lives away from the damaging impact of alcohol. We have built an organization that is committed to nurturing research for cutting-edge alcohol recovery technologies and integrating those technologies with comprehensive alcohol recovery treatment programs.

Values

BioCorRx provides the opportunity and tools to treatment centers so they can help patients live happier, healthier, and more productive lives to those suffering from alcohol addiction (as well as their family and friends) by helping them break the addiction cycle and live alcohol-free. We want patients to celebrate freedom from the past and hope for the future. Our team consists of physicians, coaches, founders and management that are committed to providing high-quality services and adherence to ethical care.

Our goal is to give our treatment center partners the ability to deliver our program in a timely, warm and compassionate way to give patients, as well as their families and friends, peace of mind. To achieve this, BioCorRx has built its program around highly-qualified alcohol addiction specialists and effective treatment solutions.

We are committed to quality and continuous improvement in order to meet our partners’ needs for an individualized program dedicated to alcohol addiction recovery.

Investors Overview

BioCorRx is uniquely poised to gain significant market share of the $22 billion annual alcohol treatment market in the US.

More than 7% of the US population ages 18 years and older or 13.8 million Americans have problems with drinking, including 8.1 million people who suffer from alcoholism. And the costs financially are staggering. Alcohol dependency and abuse costs the US over $220 billion a year. For the sake of comparison, this is greater than the amount of money spent to combat cancer ($196 billion) and obesity ($133 billion).

BioCorRx intends to distribute the program to a new clinic in the United States every 60 to 90 days. Clinics using our program are also holding discussions with major health insurance providers to pay for all or a portion of the treatment fees.

Business Model

BioCorRx’s research has discovered that demand for its services are high and that growth in highly marketed segments of the population may be achieved through partnering with additional clinic sites. The company is also exploring the sub-licensing of the program to select regions of the US and internationally.

BioCorRx's goal is to meet its growth targets through licensing opportunities by promoting its naltrexone implant product and counseling service model to existing medical clinics and treatment centers that will purchase the program and/or product from the company. In addition, Fresh Start Private intends to open corporately owned clinics in select key markets where it is deemed appropriate.

Stock Price & Charts

BioCorRx is a fully reporting company. Financial reports and other reports are available for view or by visiting the OTCBB.com online website. Audited financial reports are available quarterly.

Company Structure Details

  • Legal name: BioCorRx
    Sector: Healthcare
    Industry: Specialized Health Services
    Full Time Employees: 4
    Public Company: SEC Reporting and fully audited
    Symbol: BICX
    Exchange: OTCBB
    Outstanding: 117,800,000
    Authorized: 200,000,000
    CUSIP: 35804J102
    NAICS Code: 623220
    SIC Number: 8093
    Transfer Agent: Columbia Stock Transfer Company, 1869 E. Seltice Way #292, Post Falls, ID 83854 Tel (208) 664-3544
    CIK: 0001443863
    EIN: 26-1972677
    Year End: December 31
    State of incorporation: Nevada
    Products: Alcohol rehabilitation, exclusive naltrexone implant technology
    Address: 601 North Parkcenter Drive, Suite 103, Santa Ana, CA 92705 USA
    Investors: 858-381-4677
    Email: investors@biocorrx.com
    Website: www.biocorrx.com
Watch Jeremy Miller on Fox News!
https://www.youtube.com/watch?v=kVKgWi3_t5Y

<iframe width="560" height="315" src="; frameborder="0" allowfullscreen></iframe>www.youtube.com/embed/xhJrYqsV0VQ

<iframe width="560" height="315" src="https://www.youtube.com/watch?v=kVKgWi3_t5Y" frameborder="0" allowfullscreen></iframe>


 

BICX Chart

Key Executives

Kent Emry - CEO, Director
Brady Granier -COO, Director
Lourdes Felix -CFO, Director
Dr. Jorge Andrade, Jr. - Director
Neil Muller -Co-Founder and President, Director 

Locations
Locations of independently owned clinics using our Fresh Start Program

Start Fresh Recovery
720 N. Tustin Ave.
Suite 206
Santa Ana, CA 92705
714-541-6100
800-916-1099
www.startfreshrecovery.com 
www.stopdrinkingUSA.com

Start Fresh Executive Recovery
367 E Virginia Ave
Phoenix, AZ 85004
855-393-HOPE (4673)
www.ExecutiveRecovery.net 

Fresh Start Private Florida
1415 Panther Lane
Suites 313-320
Naples, FL 34109
800-985-7574
www.FreshStartPrivateFlorida.com 

Start Fresh Alcohol Recovery Center
2827 S. 88th St
Omaha NE 68124
402-884-1221
www.startfreshNE.com

Coming Soon!

• San Francisco, California
• Chandler, Arizona
• North Scottsdale, Arizona
• Connecticut

Insider Interview Links

December 2, 2013 - thewallstreetanalyzer.com Interview with Brady Granier COO
November 14, 2013 - SmallCapVoice Interview with Kent Emry CEO
October 2, 2013 - SmallCapVoice Interview with Brady Granier COO

 

 

SureTrader
Interactive Brokers Advertisement
BICX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#7544  Sticky Note VIVITROL is injectable naltrexone produced by Alkermes plc Pip611 09/09/16 05:15:47 PM
#10391   AMOTE1 12/15/17 08:16:36 PM
#10390   I use a PPO and ADX combo and stocktrademan 12/15/17 10:47:27 AM
#10389   I use a PPO and ADX combo and stanggt 12/15/17 10:34:56 AM
#10388   BICX buy 0.08776 stocktrademan 12/14/17 03:19:35 PM
#10387   ANAHEIM, CA, Dec. 14, 2017 (GLOBE NEWSWIRE) -- AMOTE1 12/14/17 11:26:40 AM
#10386   8-K for the CereCare investment is out. Seems Kizersosae 12/14/17 11:00:40 AM
#10385   Currently, I am in software sales...however, I traded mkjoke 12/14/17 09:10:12 AM
#10384   I think it should be mandatory that on Kizersosae 12/14/17 08:27:48 AM
#10383   Most of the time I disagree with Third Fuzzburg 12/14/17 06:37:01 AM
#10382   100k deal is a joke. First of all Thirdeyeblind 12/13/17 08:12:24 PM
#10381   You can't have it both ways...no one is mkjoke 12/13/17 04:26:15 PM
#10380   Was your friend Ralph Kramden by any chance? Kizersosae 12/13/17 03:05:21 PM
#10379   this POS stock only goes up to where PARker1703 12/13/17 02:53:00 PM
#10378   Up we gooooooo !! DREAM BIG 12/13/17 11:58:48 AM
#10377   For he last few weeks it’s been price InvestorMan18 12/13/17 11:57:33 AM
#10376   Thirdeyeblind— Titan implant is suboxone, VERY different from Brittfarin47 12/12/17 11:46:31 AM
#10375   Someone with $20,000 to buy shares when it InvestorMan18 12/12/17 11:43:15 AM
#10374   Not sure how much $100K means to their mkjoke 12/12/17 09:53:11 AM
#10373   https://finance.yahoo.com/news/biocorrx-announces-distribution-deal-cerecare-123 Kizersosae 12/12/17 07:41:59 AM
#10372   I’m now canceling my bid for 5 cents InvestorMan18 12/11/17 02:21:55 PM
#10371   Look at Therakine website, it's a joke. Look Thirdeyeblind 12/11/17 12:14:58 PM
#10370   Next month is gonna be big for us... https://t.co/ZIdboR6Tmv Kizersosae 12/11/17 11:24:43 AM
#10369   See this going to .03. Even the implant Fuzzburg 12/11/17 07:12:36 AM
#10368   Watch for the drop to .05 InvestorMan18 12/11/17 12:37:46 AM
#10367   Thanks for the recap. Will keep an eye 737Flyer 12/10/17 04:29:41 PM
#10366   Lots of links have been passed around and Kizersosae 12/10/17 03:56:25 PM
#10365   New to this stock. Seems like an interesting 737Flyer 12/10/17 11:22:58 AM
#10364   Of course. Technology not new Fuzzburg 12/09/17 08:24:53 PM
#10363   Buprenorphine is addictive so that’s why naltrexone is Pip611 12/09/17 06:46:11 PM
#10362   https://www.npr.org/sections/health-shots/2016/05/20/478577515/fda-considering-p Fuzzburg 12/09/17 01:58:59 PM
#10361   Twitter, Brady posted it. Kizersosae 12/08/17 08:18:20 PM
#10360   Kizer, The Doctors tv show which airs on InvestorMan18 12/08/17 08:15:22 PM
#10359   Glad it wasn’t you. ;) Idk if anybody in Kizersosae 12/08/17 04:45:13 PM
#10358   Little over a month before the rocket ship JB51 12/08/17 03:55:37 PM
#10357   Kizer was wrong the other day. It Fuzzburg 12/08/17 03:55:18 PM
#10356   vroom vroom stanggt 12/08/17 03:06:14 PM
#10355   I’m not mad. Why would I be? Someone Kizersosae 12/07/17 05:48:09 AM
#10354   It’s crazy how you would continue to hold InvestorMan18 12/07/17 05:22:45 AM
#10353   Haven't sold 1 share. Thinking of more. stanggt 12/06/17 02:30:33 PM
#10352   FDA is expediting the development of new addiction HOCO1 12/06/17 10:21:06 AM
#10351   I don’t get it. The stock shakes and Kizersosae 12/06/17 10:08:45 AM
#10350   The rest of the market is booming! Go Followmylead 12/06/17 09:40:32 AM
#10349   I've been trying to tell you guys this Followmylead 12/06/17 09:38:52 AM
#10348   Well that doesn't look good stanggt 12/06/17 09:36:31 AM
#10347   Still in a holding pattern for January 24th. Kizersosae 12/05/17 04:09:49 PM
#10346   Anyone hear anything from BICX? I may Fuzzburg 12/05/17 11:21:27 AM
#10345   Little action before year end !!!!!! DREAM BIG 12/05/17 09:21:38 AM
#10344   I loved today... in fact I hope today Kizersosae 11/30/17 03:24:13 PM
#10343   Guys go make some money in the booming Followmylead 11/30/17 02:54:17 PM
#10342   https://m.facebook.com/angie.denes/posts/1782692391743386 Kizersosae 11/29/17 08:45:10 PM
PostSubject